Alcon & Origenis intensify relationship


Alcon & Origenis intensify relationship

German firm Origenis has extended its research alliance with Alcon Research, to develop small molecule drugs against important ophthalmic targets, for two years.

Origenis' MOREsystem enables the directed target and indication optimized exploitation of billions of novel compounds through a proprietary multiparametric optimization process. Origenis will apply this platform to deliver preclinical candidates with indication optimized profiles for certain Alcon targets. Alcon, in turn, will bring its applied biology expertise, screening capabilities and development proficiency to the alliance.

Under the terms of the agreement, Alcon will retain the rights to any ophthalmic or nasal applications developed and will make research payments to Origenis through a series of development milestones and royalties on sales. Origenis will retain certain rights to all other uses of drug candidates discovered during the alliance.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.